## **AMENDMENTS**

## In the Claims:

Please amend claims 69-72, 74 and 75 as follows.

Please add new claims 79-81 as follows.

69. (Amended) A pharmaceutical composition that induces tolerance to an antigen, said composition comprising a non-tumor lymphoid cell or non-tumor hematopoietic cell suitable for introduction into an individual and a pharmaceutically acceptable excipient, wherein said cell contains a nucleic acid sequence encoding a fusion protein operably linked to a promoter,

said fusion protein comprising (1) an immunoglobulin heavy chain or light chain; and (2) a polypeptide containing at least one epitope of the antigen;

wherein upon introduction to the individual said composition induces tolerance to the antigen in the individual.

- 70. (Amended) The pharmaceutical composition of claim 69, wherein said nucleic acid sequence was introduced into the cell in a viral vector.
- 71. (Amended) The pharmaceutical composition of claim 70, wherein said viral vector is selected from the group consisting of retroviral vector, and baculovirus vector.
- 72. (Amended) The pharmaceutical composition of claim 70, wherein there are two or more copies of the nucleic acid sequence encoding said fusion protein of claim 69 operatively linked to said promoter.

- 74. (Amended) The pharmaceutical composition of claim 70, wherein said fusion protein comprises an N-terminal variable region of said heavy chain and has said polypeptide inserted adjacent to the first framework region of said N-terminal variable region.
- 75. (Amended) The pharmaceutical composition of claim 70, wherein the nucleic acid sequence is introduced by a virus encoding the fusion protein.
  - 79. (New) The composition of claim 69, wherein the cell is a hematopoietic cell.
  - 80. (New) The composition of claim 69 wherein the antigen is an autoimmune antigen.
  - 81. (New) The composition of claim 69 wherein the antigen is an allergan.